Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Jan 19, 2024 4:46pm

146 Views

Post# 35836652

RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

My thought was that if ONC had run the mbc trial when they had a chance, then the ADC's would have to have been competing with the onc standard of care in mbc. All indications are that the trial would have been successful. Now onc is waiting for the ADC' trials to get guidance. Bracelet was successful, Aware1 was successful and the AN bridging trial was successful and it would not have taken a biomarker for that trial to be successful.

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali